Skip to main content
Journal cover image

Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.

Publication ,  Conference
Weant, M; Dunn-Pirio, A; Peters, K; Vlahovic, G; Randazzo, D; Herndon, J; Healy, P; Threatt, S; Sampson, J; Friedman, A; Friedman, H; Desjardins, A
Published in: Neuro-Oncology

ATCT-13

Duke Scholars

Published In

Neuro-Oncology

DOI

ISSN

1522-8517

Volume

17

Issue

Suppl. 5, abstr. ATCT-13

Location

San Antonio, TX

Publisher

Oxford University Press (OUP)

Conference Name

20th Annual Scientific Meeting and Educations Day of the Society for Neuro-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weant, M., Dunn-Pirio, A., Peters, K., Vlahovic, G., Randazzo, D., Herndon, J., … Desjardins, A. (n.d.). Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. In Neuro-Oncology (Vol. 17). San Antonio, TX: Oxford University Press (OUP). https://doi.org/10.1093/neuonc/nov206.13
Weant, Mallika, Anastasie Dunn-Pirio, Katherine Peters, Gordana Vlahovic, Dina Randazzo, James Herndon, Patrick Healy, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.” In Neuro-Oncology, Vol. 17. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov206.13.
Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, et al. Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. In: Neuro-Oncology. Oxford University Press (OUP);
Weant, Mallika, et al. “Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.Neuro-Oncology, vol. 17, no. Suppl. 5, abstr. ATCT-13, Oxford University Press (OUP). Manual, doi:10.1093/neuonc/nov206.13.
Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, Healy P, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial. Neuro-Oncology. Oxford University Press (OUP);
Journal cover image

Published In

Neuro-Oncology

DOI

ISSN

1522-8517

Volume

17

Issue

Suppl. 5, abstr. ATCT-13

Location

San Antonio, TX

Publisher

Oxford University Press (OUP)

Conference Name

20th Annual Scientific Meeting and Educations Day of the Society for Neuro-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences